Our goals are to further characterize the physiologic features, biochemical mechanisms, and therapeutic implications of two observations we have recently made regarding oxidative injury of mammalian cells: (1) that the monokines tumor necrosis factor (TNF) and the lymphokine lymphotoxin (LT), alone of the cytokines tested, trigger a massive respiratory burst from human neutrophils (PMN), but not from monocytes, only after an unprecedentedly prolonged lag period, and only if the PMN are adherent to suitable surfaces, including human unbilical vein endothelial cells (HUVEC), and (2) that the alpha-ketoacid pyruvate is selectively secreted by mammalian cells, acts in the medium as a scavenger of H202 via its rapid, nonenzymatic, oxidative decarboxylation, and acts intracellularly as a target of oxidative injury that may compromise cellular energy supply. For (1), we will further characterize the nature of surfaces that permit the PMN response to TNF and LT, analyze the dependence on adherence with special attention to effects on the number, affinity, clustering, and internalization of TNF receptors, and investigate the basis of the long lag period in response to these agents, in terms of possible induction of a transient suppressive state and the timing of signal transduction reactions, especially those leading to activation, translocation and myristoylation of protein kinase C. For (2), we will analyze the mechanism of pyruvate export, with special attention to HUVEC, quantify the contribution of pyruvate to cell buffering capacity against H202, and analyze the enzymatic basis for the variability in resistance of pyruvate secretory capacity to oxidative inactivation in H202-sensitive versus -resistant cells. Finally, (3) we will test the role of PMN-derived H202, and the antioxidant properties of exogenous pyruvate, in mice with pulmonary inflammation induced by complement activation, in TNF-induced hemorrhagic necrosis, and in TNF-induced lethality.

Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Rockefeller University
Department
Type
DUNS #
071037113
City
New York
State
NY
Country
United States
Zip Code
10065
Haslett, P; Hempstead, M; Seidman, C et al. (1997) The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 13:1047-54
Moreira, A L; Corral, L G; Ye, W et al. (1997) Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res Hum Retroviruses 13:857-63
Klausner, J D; Makonkawkeyoon, S; Akarasewi, P et al. (1996) The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 11:247-57
Bender, A; Sapp, M; Schuler, G et al. (1996) Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 196:121-35
Berman, M E; Xie, Y; Muller, W A (1996) Roles of platelet/endothelial cell adhesion molecule-1 (PECAM-1, CD31) in natural killer cell transendothelial migration and beta 2 integrin activation. J Immunol 156:1515-24
Frankel, S S; Wenig, B M; Burke, A P et al. (1996) Replication of HIV-1 in dendritic cell-derived syncytia at the mucosal surface of the adenoid. Science 272:115-7
Granelli-Piperno, A; Moser, B; Pope, M et al. (1996) Efficient interaction of HIV-1 with purified dendritic cells via multiple chemokine coreceptors. J Exp Med 184:2433-8
Berman, M E; Muller, W A (1995) Ligation of platelet/endothelial cell adhesion molecule 1 (PECAM-1/CD31) on monocytes and neutrophils increases binding capacity of leukocyte CR3 (CD11b/CD18). J Immunol 154:299-307
Granelli-Piperno, A; Pope, M; Inaba, K et al. (1995) Coexpression of NF-kappa B/Rel and Sp1 transcription factors in human immunodeficiency virus 1-induced, dendritic cell-T-cell syncytia. Proc Natl Acad Sci U S A 92:10944-8
Muller, W A (1995) The role of PECAM-1 (CD31) in leukocyte emigration: studies in vitro and in vivo. J Leukoc Biol 57:523-8

Showing the most recent 10 out of 88 publications